Johnson & Johnson MedTech, a leader in neurovascular care, today announced the expansion of its Research, Development and Innovation (RD&I) activities in Galway.
The Galway site is a hub for the company’s NTI and RD&I efforts. NTI is focused on understanding unmet needs in neurovascular disease and driving innovation in stroke treatment at the company’s Galway-based centre of excellence.
Following a previous expansion announced in 2022, this latest endeavor will enable Johnson & Johnson MedTech to expand stroke-specific and liquid embolic procedural R&D capabilities in Galway, deepen its bench of engineering and scientific talent, and accelerate the development of new treatment solutions for patients with acute ischemic and hemorrhagic stroke – two of the leading causes of disability and death worldwide
IDA Ireland works with Johnson & Johnson MedTech in Galway and across its Irish operations.
Minister for Enterprise, Tourism and Employment Peter Burke TD said: “This expansion by Johnson & Johnson MedTech is a powerful endorsement of Ireland’s position as a global leader in MedTech innovation. The Galway site continues to attract world-class investment and talent, and today’s announcement will further our capabilities in neurovascular research and stroke care. The Government welcomes this announcement which will not only enhance our innovation ecosystem but also deliver real impact for patients worldwide.”
Minister for Education and Youth of Ireland, Hildegarde Naughton TD said: 'This Johnson & Johnson Neurovascular R&D centre underscores Ireland's status as a global leader in medical technologies. This investment further strengthens our reputation for research excellence. The expanded facility will be pivotal in advancing stroke treatment innovation. I wish Johnson & Johnson continued success.”
Michael Gilvarry, Head of R&D for J&J MedTech Neurovascular and General Manager of the Galway site said: “By expanding our remit from ischemic stroke to include chronic subdural hematoma, and other neurovascular conditions, our talented workforce in Galway is applying their scientific knowledge and engineering skills in new ways to find solutions to these life-threatening conditions. Ireland is a critical part of our global innovation network, and this investment reflects our long-term commitment to building and advancing our neurovascular capabilities in the region for the benefit of patients around the world.”
Johnson & Johnson MedTech established its presence in Galway in 2017 and has continually invested in scaling engineering, RD&I and manufacturing capabilities focused on neurovascular research, product development, and supply chain. Today’s announcement builds on an initial R&D investment in 2022, including the development of a state-of-the-art innovation centre, which was completed earlier this year.
IDA Ireland CEO Michael Lohan said, “Galway and the West Region has long been a cornerstone of Europe’s medical technology sector, and our ongoing partnership with Johnson & Johnson MedTech in the neurovascular space is a shining example of the region’s status as a key innovation hub. The work at the Galway site, which is closely aligned to our new strategy, Adapt Intelligently will not only create high-skilled opportunities for local talent but will also help shape the future of stroke care through cutting-edge innovation developed here in the west of Ireland.”
The announcement coincides with a convening of Johnson & Johnson MedTech’s Neurovascular Global Scientific Advisory Board in Galway, a first for the Ireland facility and team, where physician leaders from across the U.S., EMEA and Asia-Pacific are gathering to shape future directions in stroke technology and care.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit https://www.jnjmedtech.com/en-US/companies/cerenovus and connect on LinkedIn and X.
The Galway site is a hub for the company’s NTI and RD&I efforts. NTI is focused on understanding unmet needs in neurovascular disease and driving innovation in stroke treatment at the company’s Galway-based centre of excellence.
Following a previous expansion announced in 2022, this latest endeavor will enable Johnson & Johnson MedTech to expand stroke-specific and liquid embolic procedural R&D capabilities in Galway, deepen its bench of engineering and scientific talent, and accelerate the development of new treatment solutions for patients with acute ischemic and hemorrhagic stroke – two of the leading causes of disability and death worldwide
IDA Ireland works with Johnson & Johnson MedTech in Galway and across its Irish operations.
Minister for Enterprise, Tourism and Employment Peter Burke TD said: “This expansion by Johnson & Johnson MedTech is a powerful endorsement of Ireland’s position as a global leader in MedTech innovation. The Galway site continues to attract world-class investment and talent, and today’s announcement will further our capabilities in neurovascular research and stroke care. The Government welcomes this announcement which will not only enhance our innovation ecosystem but also deliver real impact for patients worldwide.”
Minister for Education and Youth of Ireland, Hildegarde Naughton TD said: 'This Johnson & Johnson Neurovascular R&D centre underscores Ireland's status as a global leader in medical technologies. This investment further strengthens our reputation for research excellence. The expanded facility will be pivotal in advancing stroke treatment innovation. I wish Johnson & Johnson continued success.”
Michael Gilvarry, Head of R&D for J&J MedTech Neurovascular and General Manager of the Galway site said: “By expanding our remit from ischemic stroke to include chronic subdural hematoma, and other neurovascular conditions, our talented workforce in Galway is applying their scientific knowledge and engineering skills in new ways to find solutions to these life-threatening conditions. Ireland is a critical part of our global innovation network, and this investment reflects our long-term commitment to building and advancing our neurovascular capabilities in the region for the benefit of patients around the world.”
Johnson & Johnson MedTech established its presence in Galway in 2017 and has continually invested in scaling engineering, RD&I and manufacturing capabilities focused on neurovascular research, product development, and supply chain. Today’s announcement builds on an initial R&D investment in 2022, including the development of a state-of-the-art innovation centre, which was completed earlier this year.
IDA Ireland CEO Michael Lohan said, “Galway and the West Region has long been a cornerstone of Europe’s medical technology sector, and our ongoing partnership with Johnson & Johnson MedTech in the neurovascular space is a shining example of the region’s status as a key innovation hub. The work at the Galway site, which is closely aligned to our new strategy, Adapt Intelligently will not only create high-skilled opportunities for local talent but will also help shape the future of stroke care through cutting-edge innovation developed here in the west of Ireland.”
The announcement coincides with a convening of Johnson & Johnson MedTech’s Neurovascular Global Scientific Advisory Board in Galway, a first for the Ireland facility and team, where physician leaders from across the U.S., EMEA and Asia-Pacific are gathering to shape future directions in stroke technology and care.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit https://www.jnjmedtech.com/en-US/companies/cerenovus and connect on LinkedIn and X.